Scribe Therapeutics IPO
Scribe Therapeutics is a biotechnology company developing next-generation CRISPR-based genetic medicines for serious diseases. The company focuses on creating improved gene editing systems and in vivo delivery technologies to expand the therapeutic potential of gene editing beyond current limitations.
Key Facts
| Industry | Biotechnology |
| Founded | 2018 |
| Headquarters | South San Francisco, CA |
| Employees | ~200 |
| Funding | Series D funding. Total raised over $420 million across multiple rounds. IPO filed targeting $100-107 million at $13-$15 per share. |
About Scribe Therapeutics
Scribe Therapeutics is a biotechnology company founded to advance the next generation of CRISPR-based genetic medicines. The company was established by prominent CRISPR pioneers and focuses on engineering improved molecular machinery for gene editing, including novel CRISPR enzymes (CASs) and delivery systems. Scribe's platform approach aims to overcome current limitations in gene editing, such as delivery challenges, off-target effects, and limited tissue accessibility.
The company operates two main platforms: CRISPR by Design (CbD), which engineers optimized CRISPR systems, and XE platform for next-generation gene editors. Scribe is developing therapies for serious diseases across multiple therapeutic areas, including genetic disorders, oncology, and other conditions where precise gene editing could provide transformative treatment options. The company's approach differentiates itself by building proprietary editing systems rather than relying solely on naturally occurring CRISPR enzymes.
Scribe Therapeutics occupies an important position in the rapidly evolving gene editing landscape, competing with both established public companies and well-funded private competitors. The company's success in developing improved gene editing tools and demonstrating clinical potential will be critical factors in its eventual path to public markets.
IPO Status
Scribe Therapeutics has officially filed for an initial public offering with the SEC, setting terms for a $100-107 million raise. The company plans to sell 7.15 million shares at a price range of $13-$15 per share, with trading expected under the ticker symbol SCTX. The proceeds will fund clinical development of the company's CRISPR-based genetic medicines, particularly focusing on lipid-lowering therapies for cardiovascular disease. The IPO filing represents a significant milestone for the CRISPR gene editing company, which has raised over $420 million in venture capital through its Series D funding round. Scribe has developed proprietary gene editing platforms for both ex vivo and in vivo therapies and has attracted strategic backing from major pharmaceutical companies including Sanofi. The company's founding ties to UC Berkeley and Nobel Prize winner Jennifer Doudna have been highlighted as the company prepares to go public. The timing of the offering reflects management's confidence in advancing their pipeline programs and capitalizing on investor interest in CRISPR therapeutics.
Competitors
Frequently Asked Questions
Does Scribe Therapeutics have a stock?
No, Scribe Therapeutics has not had an IPO yet. The company remains privately held and is focused on advancing its CRISPR-based gene editing platforms and therapeutic programs. Sign up for alerts to stay informed.
When is the Scribe Therapeutics IPO date?
Scribe Therapeutics has not announced an IPO date. While the company is considered a potential IPO candidate given its funding and development stage, no official filing or timeline has been disclosed. Sign up for alerts to stay informed.
How can I buy Scribe Therapeutics stock?
You cannot currently buy Scribe Therapeutics stock as the company is privately held. If and when the company goes public, shares would become available through brokerage accounts on public exchanges. Sign up for alerts to stay informed.
Stay Updated on the Scribe Therapeutics IPO
Get real-time alerts when Scribe Therapeutics files for an IPO, prices shares, or begins trading.
Get IPO Alerts